Assessment of the response of patients with Crohn's disease to biological therapy using new non-invasive markers: lactoferrin and calprotectin.
Nogueira, Islaine Martins; Miszputen, Sender Jankiel; Ambrogini, Orlando; Artigiani-Neto, Ricardo; Carvente, Cláudia Teresa; Zanon, Maria Ivani.
; 50(2): 130-7, 2013 04.
Artigo em Inglês | MEDLINE | ID: mdl-23903623
Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease.
Postepowanie w chorobie Lesniowskiego-Crohna step-up czy top-down?
Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease.
[Platelet count predicts therapeutic response of infliximab for active Crohn's disease].
[Analysis of factors relevant to primary non-response to infliximab treatment in patients with Crohn's disease].
ACG Clinical Guideline: Management of Crohn's Disease in Adults.
Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis.
[Efficacy of infliximab in the treatment of Crohn's disease in children].
The mouth in inflammatory bowel disease and aspects of orofacial granulomatosis.
Infliximab preferentially induces clinical remission and mucosal healing in short course Crohn's disease with luminal lesions through balancing abnormal immune response in gut mucosa.